Revisiting the standard of care for immune checkpoint inhibitors in early-stage triple-negative breast cancer: timing, duration, dose, combination, and patient selection.
- DOI
- 10.3389/fimmu.2026.1795426
- Published
- 2026
- Container
- Frontiers in immunology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3389/fimmu.2026.1795426,
title = {Revisiting the standard of care for immune checkpoint inhibitors in early-stage triple-negative breast cancer: timing, duration, dose, combination, and patient selection.},
author = {Guo X and Li P and Wu W and Wang Y and Qiu J and Ma Q and Guo X and Liu K and Wang Y and Ruan W and Tao S and Xu Z and Shi Y and Zhou Y},
year = {2026},
journal = {Frontiers in immunology},
doi = {10.3389/fimmu.2026.1795426},
url = {https://doi.org/10.3389/fimmu.2026.1795426}
}RIS
TY - JOUR TI - Revisiting the standard of care for immune checkpoint inhibitors in early-stage triple-negative breast cancer: timing, duration, dose, combination, and patient selection. AU - Guo X AU - Li P AU - Wu W AU - Wang Y AU - Qiu J AU - Ma Q AU - Guo X AU - Liu K AU - Wang Y AU - Ruan W AU - Tao S AU - Xu Z AU - Shi Y AU - Zhou Y PY - 2026 JO - Frontiers in immunology DO - 10.3389/fimmu.2026.1795426 UR - https://doi.org/10.3389/fimmu.2026.1795426 ER -
APA
X, G., P, L., W, W., Y, W., J, Q., Q, M., X, G., K, L., Y, W., W, R., S, T., Z, X., Y, S., & Y, Z. (2026). Revisiting the standard of care for immune checkpoint inhibitors in early-stage triple-negative breast cancer: timing, duration, dose, combination, and patient selection.. Frontiers in immunology. https://doi.org/10.3389/fimmu.2026.1795426
Source records
- pubmed · retrieved 2026-09-26T00:39:42.226Z